The drug was approved in combination with Pfizer’s Inlyta to treat advanced renal cell carcinoma.
Merck & Co’s blockbuster drug Keytruda met the main goal of a late-stage trial testing the treatment in patients with cancers of the digestive tract, the US drugmaker said on Wednesday. Keytruda, among a class of medicines called PD-1 inhibitors, is Merck’s top selling drug and has already been approved to treat several forms of cancer including skin and lung cancer. PD-1 or PD-L1 inhibitors work by blocking a mechanism of tumors that allows them to evade detection by cancer-fighting cells. Keytruda, when…